Transcription/NN
factor/NN
activation/NN
in/IN
lymphokine/NN
activated/JJ
killer/NN
cells/NNS
and/CC
lymphocytes/NNS
from/IN
patients/NNS
receiving/VBG
IL-2/NN
immunotherapy/NN
./.

Administration/NN
of/IN
the/DT
cytokine/NN
interleukin-2/NN
(/(
IL-2/NN
)/)
can/MD
result/VB
in/IN
therapeutic/JJ
benefits/NNS
for/IN
individuals/NNS
with/IN
renal/JJ
cell/NN
carcinoma/NN
and/CC
melanoma/NN
./.
=====
Here/RB
we/PRP
report/VBP
an/DT
analysis/NN
of/IN
the/DT
transcription/NN
factor/NN
families/NNS
AP-1/NN
,/,
Sp1/NN
,/,
NF-kappaB/NN
,/,
and/CC
signal/NN
transducers/NNS
and/CC
activators/NNS
of/IN
transcription/NN
(/(
STAT/NN
)/)
in/IN
cancer/NN
patients/NNS
'/POS
lymphocytes/NNS
before/IN
and/CC
after/IN
IL-2/NN
immunotherapy/NN
,/,
as/IN
assessed/VBN
by/IN
a/DT
gel-shift/JJ
assay/NN
./.
=====
An/DT
in/FW
vitro/FW
surrogate/NN
of/IN
IL-2/NN
immunotherapy/NN
is/VBZ
the/DT
incubation/NN
of/IN
fresh/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NNS
)/)
from/IN
healthy/JJ
individuals/NNS
in/IN
IL-2/NN
for/IN
several/JJ
days/NNS
,/,
resulting/VBG
in/IN
the/DT
production/NN
of/IN
lymphokine-activated/JJ
killer/NN
(/(
LAK/NN
)/)
activity/NN
in/IN
these/DT
cultures/NNS
./.
=====
One/CD
purpose/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
describe/VB
the/DT
profile/NN
of/IN
transcription/NN
factor/NN
activation/NN
in/IN
these/DT
different/JJ
populations/NNS
,/,
and/CC
assess/VB
whether/IN
the/DT
patterns/NNS
observed/VBN
correlated/VBD
with/IN
functional/JJ
differences/NNS
in/IN
these/DT
cells/NNS
./.
=====
Prior/JJ
to/TO
in/FW
vivo/FW
IL-2/NN
administration/NN
,/,
the/DT
typical/JJ
binding/NN
pattern/NN
of/IN
transcription/NN
factors/NNS
in/IN
PBMC/NNS
from/IN
patients/NNS
resembled/VBD
that/DT
seen/VBN
in/IN
fresh/JJ
PBMC/NNS
from/IN
healthy/JJ
individuals/NNS
./.
=====
Over/IN
a/DT
3-week/JJ
course/NN
of/IN
IL-2/NN
therapy/NN
,/,
in/IN
most/JJS
patients/NNS
the/DT
binding/NN
patterns/NNS
of/IN
AP-1/NN
,/,
Sp1/NN
,/,
and/CC
NF-kappaB/NN
proteins/NNS
changed/VBD
to/TO
resemble/VB
those/DT
seen/VBN
in/IN
PBMC/NNS
activated/VBN
by/IN
IL-2/NN
in/FW
vitro/FW
./.
=====
However/RB
,/,
the/DT
cells/NNS
obtained/VBN
from/IN
IL-2-treated/JJ
patients/NNS
did/VBD
not/RB
have/VB
low-level/JJ
constitutive/JJ
expression/NN
of/IN
STAT/NN
binding/NN
factors/NNS
as/IN
did/VBD
LAK/NN
cells/NNS
./.
=====
When/WRB
these/DT
patient/NN
cells/NNS
were/VBD
further/RB
stimulated/VBN
by/IN
IL-2/NN
in/FW
vitro/FW
,/,
additional/JJ
differences/NNS
in/IN
STAT/NN
induction/NN
patterns/NNS
were/VBD
noted/VBN
./.
=====
These/DT
data/NNS
provide/VBP
further/JJ
information/NN
on/IN
the/DT
molecular/JJ
events/NNS
occurring/VBG
in/IN
immune/JJ
cells/NNS
generated/VBN
through/IN
in/FW
vivo/FW
and/CC
in/FW
vitro/FW
administration/NN
of/IN
IL-2/NN
,/,
and/CC
further/RB
document/VBP
that/IN
there/EX
is/VBZ
not/RB
a/DT
precise/JJ
congruence/NN
between/IN
PBMC/NNS
activated/VBN
in/FW
vivo/FW
and/CC
in/FW
vitro/FW
by/IN
IL-2/NN
./.